AU2003243696B2 - Quick dissolve compositions and tablets based thereon - Google Patents

Quick dissolve compositions and tablets based thereon Download PDF

Info

Publication number
AU2003243696B2
AU2003243696B2 AU2003243696A AU2003243696A AU2003243696B2 AU 2003243696 B2 AU2003243696 B2 AU 2003243696B2 AU 2003243696 A AU2003243696 A AU 2003243696A AU 2003243696 A AU2003243696 A AU 2003243696A AU 2003243696 B2 AU2003243696 B2 AU 2003243696B2
Authority
AU
Australia
Prior art keywords
dosage form
oral dosage
mix
pearlitol
syloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003243696A
Other languages
English (en)
Other versions
AU2003243696A1 (en
Inventor
Steven Frisbee
Mark Herman
Naima Mezaache
Patrick Woodall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant International Bermuda
Original Assignee
Valeant International Barbados SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant International Barbados SRL filed Critical Valeant International Barbados SRL
Publication of AU2003243696A1 publication Critical patent/AU2003243696A1/en
Assigned to BIOVAIL LABORATORIES INTERNATIONAL S.R.L. reassignment BIOVAIL LABORATORIES INTERNATIONAL S.R.L. Request for Assignment Assignors: BIOVAIL LABORATORIES INC.
Application granted granted Critical
Publication of AU2003243696B2 publication Critical patent/AU2003243696B2/en
Assigned to VALEANT INTERNATIONAL (BARBADOS) SRL reassignment VALEANT INTERNATIONAL (BARBADOS) SRL Request to Amend Deed and Register Assignors: EVOLVA LTD
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AU2003243696A 2002-06-21 2003-06-23 Quick dissolve compositions and tablets based thereon Ceased AU2003243696B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/176,135 US7815937B2 (en) 1998-10-27 2002-06-21 Quick dissolve compositions and tablets based thereon
US10/176,135 2002-06-21
PCT/US2003/019527 WO2004000197A2 (en) 2002-06-21 2003-06-23 Quick dissolve compositions and tablets based thereon

Publications (2)

Publication Number Publication Date
AU2003243696A1 AU2003243696A1 (en) 2004-01-06
AU2003243696B2 true AU2003243696B2 (en) 2008-10-09

Family

ID=29999057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003243696A Ceased AU2003243696B2 (en) 2002-06-21 2003-06-23 Quick dissolve compositions and tablets based thereon

Country Status (8)

Country Link
US (1) US7815937B2 (enExample)
EP (1) EP1553909A4 (enExample)
JP (2) JP2005535622A (enExample)
AU (1) AU2003243696B2 (enExample)
CA (1) CA2490365A1 (enExample)
MX (1) MXPA04012877A (enExample)
NZ (1) NZ537744A (enExample)
WO (1) WO2004000197A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
EP1128817A1 (en) * 1998-10-27 2001-09-05 Biovail Technologies Ltd Microparticles containing peg and/or peg glyceryl esters
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
CA2392486A1 (en) * 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US8349361B2 (en) * 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
WO2005044006A1 (en) * 2003-11-05 2005-05-19 Battelle Memorial Institute Quick dissolving agrochemical products
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20050244343A1 (en) * 2004-04-30 2005-11-03 Withiam Michael C Oral care products comprising silica
US20050244492A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Rapidly disintegrating tablets comprising titanium dioxide
US20070196476A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area titanium dioxide
US20070196474A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
US20070196477A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area calcium phosphates
US20070196475A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising silica materials
US20050244493A1 (en) * 2004-04-30 2005-11-03 Withiam Michael C Rapidly disintegrating tablets comprising calcium carbonate
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2005123040A1 (ja) * 2004-06-22 2005-12-29 Shionogi & Co., Ltd. 口腔内速崩壊錠
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
WO2007075408A2 (en) * 2005-12-16 2007-07-05 Effrx, Inc. Effervescent compositions for triptans
CN101431895A (zh) * 2006-05-01 2009-05-13 卡普里康制药公司 新颖的曲坦制剂和制备它们的方法
FR2910319B1 (fr) * 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
CA2673458A1 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US8568780B2 (en) * 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
CA2704209C (en) * 2007-10-31 2017-02-28 Mcneil-Ppc, Inc. Orally disintegrative dosage form
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
JP5608653B2 (ja) * 2008-09-04 2014-10-15 ファーナム・カンパニーズ・インコーポレーテッド チュアブルな徐放性製剤
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
CN102458475B (zh) 2009-05-20 2016-03-30 大日本住友制药株式会社 压制包衣的口腔崩解片
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
TR201901905T4 (tr) 2009-12-11 2019-03-21 Sumitomo Dainippon Pharma Co Ltd Kuru kaplanmış ağızda dağılan tablet.
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
WO2013115171A1 (ja) * 2012-02-03 2013-08-08 旭化成ケミカルズ株式会社 苦味マスク顆粒含有口腔内崩壊錠
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
JP6045238B2 (ja) * 2012-07-27 2016-12-14 旭化成株式会社 増粘多糖類を含む錠剤
EP2880011A4 (en) * 2012-08-01 2016-03-23 Acura Pharmaceuticals Inc STABILIZATION OF SYNTHESIS SYSTEMS OF METHAMPHETAMINE IN SINGLE PREGNANCY
EP3091966B1 (en) 2014-01-10 2019-07-31 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
DK3166597T3 (en) 2014-07-11 2025-09-01 Azanta Danmark As Misoprostol dispersibel tablet
US20160008310A1 (en) * 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
IL314380A (en) 2016-10-06 2024-09-01 Orbus Therapeutics Inc Preparations for administration of aflornithine
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CA3194494A1 (en) 2020-09-29 2022-04-07 Millicent Pharma Limited Orodispersible formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5438167B2 (enExample) * 1974-04-27 1979-11-19
PH20837A (en) * 1983-04-29 1987-05-08 Pennwalt Corp Rapid dissolving uniform drug compositon
FR2571046B1 (fr) * 1984-10-03 1987-10-16 Roquette Freres Procede de preparation de mannitol granulaire directement compressible
US5536526A (en) * 1988-01-11 1996-07-16 Cultor Ltd. Xylitol-based binding and diluting agent and a process for the production thereof
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5204115A (en) * 1990-12-12 1993-04-20 Suomen Xyrofin Oy Directly compressible xylitol and method
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6468959B1 (en) * 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
JP3125565B2 (ja) * 1994-03-25 2001-01-22 松下電器産業株式会社 画像符号化方法
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5686720A (en) 1995-03-02 1997-11-11 Hewlett Packard Company Method and device for achieving high contrast surface illumination
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
PT1001748E (pt) * 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
ATE209911T1 (de) * 1997-10-03 2001-12-15 Warner Lambert Co Gepresste nitroglycerintablette und verfahren zu ihrer herstellung
JP2002528042A (ja) 1997-10-07 2002-08-27 フイズ テクノロジーズ リミテッド 改善された放出特性を有する投与形態
US5965167A (en) * 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
NZ505123A (en) * 1997-12-19 2003-07-25 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof
DE69901938T3 (de) * 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
EP1128817A1 (en) 1998-10-27 2001-09-05 Biovail Technologies Ltd Microparticles containing peg and/or peg glyceryl esters
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
FR2790387B1 (fr) 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
DE19931708A1 (de) * 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
GB0001315D0 (en) * 2000-01-20 2000-03-08 Novartis Ag Organic compounds
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
JP2002154988A (ja) * 2000-11-21 2002-05-28 Taiyo Yakuhin Kogyo Kk 口腔内崩壊錠剤およびその製造方法
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
KR20030074810A (ko) 2001-02-08 2003-09-19 파마시아 코포레이션 성 기능장애의 치료를 위한 신속-발현 약
AU2001241730B2 (en) 2001-02-23 2007-03-15 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
HUP0400098A2 (hu) 2001-02-27 2004-04-28 Ranbaxy Laboratories Limited Gyorsan kioldódó ciklooxigenáz-2 enzimgátló hatóanyagot tartalmazó tabletták és eljárás az előállításukra
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
BR0205509A (pt) * 2001-07-27 2003-06-24 Yamanouchi Pharma Co Ltd Composição compreendendo partìculas finas de liberação prolongada para comprimidos de rápida desintegração na cavidade bucal e método de fabricação da mesma
EP1432410A2 (en) 2001-09-25 2004-06-30 Ranbaxy Laboratories, Ltd. Process for the preparation of fast dissolving effervescent dosage form
CZ2004456A3 (cs) 2001-10-10 2005-03-16 Pharmacia Corporation Kompozice na bázi valdekoxibu připravená rozprašovacím sušením, která se rozpadá v ústech
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US20040137060A1 (en) * 2002-05-13 2004-07-15 Siobhan Fogarty Enalapril microspheres, dosage forms and chronotherapeutic methods based thereon
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents

Also Published As

Publication number Publication date
EP1553909A2 (en) 2005-07-20
EP1553909A4 (en) 2007-11-28
CA2490365A1 (en) 2003-12-31
MXPA04012877A (es) 2005-07-05
US7815937B2 (en) 2010-10-19
US20030124184A1 (en) 2003-07-03
JP2011079864A (ja) 2011-04-21
JP2005535622A (ja) 2005-11-24
AU2003243696A1 (en) 2004-01-06
WO2004000197A2 (en) 2003-12-31
NZ537744A (en) 2010-03-26
WO2004000197A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
AU2003243696B2 (en) Quick dissolve compositions and tablets based thereon
US6048541A (en) Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US20120082729A1 (en) Quick dissolve compositions and tablets based thereon
EP1124540B1 (en) Dosage forms containing taste masked active agents
US6086920A (en) Disintegratable microspheres
CA2405190C (en) Simethicone solid oral dosage form
US8496969B2 (en) Soft tablet containing high molecular weight cellulosics
US5980941A (en) Self-binding shearform compositions
US20090104267A1 (en) Soft tablet containing high molecular weight cellulosics
EP0996427A1 (en) Process for improving flow and compression of tableting compositions
CA2472432C (en) Soft tablet containing high molecular weight cellulosics

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.

Free format text: FORMER APPLICANT(S): BIOVAIL LABORATORIES INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired